Expanding role of lenalidomide in hematologic malignancies

References

• HenryJYLabartheMCMeyerBDasguptaPDalgleishAGGalustianCEnhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomideImmunology201313937738523374145
   PubMed Web of Science ®Google Scholar
• CastelliRCassinRCannavòACugnoMImmunomodulatory drugs: new options for the treatment of myelodysplastic syndromesClin Lymphoma Myeloma Leuk2013131723153925
   PubMed Web of Science ®Google Scholar
• LeBlancRHideshimaTCatleyLPImmunomodulatory drug costimulates T cells via the B7-CD28 pathwayBlood20041031787179014512311
   PubMed Web of Science ®Google Scholar
• DredgeKMarriottJBMacdonaldCDNovel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effectsBr J Cancer2002871166117212402158
   PubMed Web of Science ®Google Scholar
• MartinianiRDi LoretoVDi SanoCLombardoALiberatiAMBiological activity of lenalidomide and its underlying therapeutic effects in multiple myelomaAdv Hematol2012201284294522919394
   PubMedGoogle Scholar
• MitsiadesCSMitsiadesNSRichardsonPGMunshiNCAndersonKCMultiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironmentJ Cell Biochem200710195096817546631
   PubMed Web of Science ®Google Scholar
• VerhelleDCorralLGWongKLenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cellsCancer Res20076774675517234786
   PubMed Web of Science ®Google Scholar
• Escoubet-LozachLLinILJensen-PergakesKPomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanismCancer Res2009697347735619738071
   PubMed Web of Science ®Google Scholar
• ItoTAndoHSuzukiTIdentification of a primary target of thalidomide teratogenicityScience20103271345135020223979
   PubMed Web of Science ®Google Scholar
• Lopez-GironaAMendyDItoTCereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomideLeukemia2012262326233522552008
   PubMed Web of Science ®Google Scholar
• ZhangLHKosekJWangMHeiseCSchaferPHChopraRLenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expressionBr J Haematol201316048750223252516
   PubMed Web of Science ®Google Scholar
• ZhuYXBraggioEShiCXCereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomideBlood20111184771477921860026
   PubMed Web of Science ®Google Scholar
• HeintelDRocciALudwigHHigh expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasoneBr J Haematol201316169570023565715
   PubMed Web of Science ®Google Scholar
• LuGMiddletonRESunHThe myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteinsScience201434330530924292623
   PubMed Web of Science ®Google Scholar
• FinkECKrönkeJHurstSNLenalidomide Induces Ubiquitination and Degradation of CSNK1A1 in MDS with Del(5q)ASH Annual Meeting Abstracts2014124
   Google Scholar
• HsuAKQuachHTaiTThe immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapyBlood20111171605161320978269
   PubMed Web of Science ®Google Scholar
• KumarSRajkumarSVThalidomide and lenalidomide in the treatment of multiple myelomaEur J Cancer2006421612162216750621
   PubMed Web of Science ®Google Scholar
• KastritisEDimopoulosMAThe evolving role of lenalidomide in the treatment of hematologic malignanciesExpert Opin Pharmacother2007849750917309344
   PubMed Web of Science ®Google Scholar
• RichardsonPGSchlossmanRLWellerEImmunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood20021003063306712384400
   PubMed Web of Science ®Google Scholar
• WeberDMChenCNiesvizkyRLenalidomide plus dexamethasone for relapsed multiple myeloma in North AmericaN Engl J Med20073572133214218032763
   PubMed Web of Science ®Google Scholar
• DimopoulosMSpencerAAttalMLenalidomide plus dexamethasone for relapsed or refractory multiple myelomaN Engl J Med20073572123213218032762
   PubMed Web of Science ®Google Scholar
• DimopoulosMAChenCSpencerALong-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myelomaLeukemia2009232147215219626046
   PubMed Web of Science ®Google Scholar
• StewartAKRajkumarSVDimopoulosMACarfilzomib, lenalidomide, and dexamethasone for relapsed multiple myelomaN Engl J Med201537214215225482145
   PubMed Web of Science ®Google Scholar
• ZonderJACrowleyJHusseinMALenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232)Blood20101165838584120876454
   PubMed Web of Science ®Google Scholar
• RajkumarSVJacobusSCallanderNSLenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialLancet Oncol201011293719853510
   PubMed Web of Science ®Google Scholar
• BenboubkerLDimopoulosMADispenzieriALenalidomide and dexamethasone in transplant-ineligible patients with myelomaN Engl J Med201437190691725184863
   PubMed Web of Science ®Google Scholar
• AttalMLauwers-CancesVMaritGLenalidomide maintenance after stem-cell transplantation for multiple myelomaN Engl J Med20123661782179122571202
   PubMed Web of Science ®Google Scholar
• McCarthyPLOwzarKHofmeisterCCLenalidomide after stem-cell transplantation for multiple myelomaN Engl J Med20123661770178122571201
   PubMed Web of Science ®Google Scholar
• PalumboAHajekRDelforgeMContinuous lenalidomide treatment for newly diagnosed multiple myelomaN Engl J Med20123661759176922571200
   PubMed Web of Science ®Google Scholar
• KumarSKBerdejaJGNiesvizkyRSafety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 studyLancet Oncol2014151503151225456369
   PubMed Web of Science ®Google Scholar
• PalumboAAndersonKMultiple myelomaN Engl J Med20113641046106021410373
   PubMed Web of Science ®Google Scholar
• CorsoALorenziATerullaVModification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasoneAnn Hematol20048358859115235749
   PubMed Web of Science ®Google Scholar
• ZangariMSaghafifarFAnaissieEActivated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complicationsBlood Coagul Fibrinolysis20021318719211943931
   PubMed Web of Science ®Google Scholar
• PalumboABringhenSKumarSKSecond primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient dataLancet Oncol20141533334224525202
   PubMed Web of Science ®Google Scholar
• ThomasAMailankodySKordeNKristinssonSYTuressonILandgrenOSecond malignancies after multiple myeloma: from 1960s to 2010sBlood20121192731273722310913
   PubMed Web of Science ®Google Scholar
• JerezAGondekLPJankowskaAMTopography, clinical, and genomic correlates of 5q myeloid malignancies revisitedJ Clin Oncol2012301343134922370328
   PubMed Web of Science ®Google Scholar
• SwerdlowSHCampoEHarrisNLWHO Classification of Tumours of Haematopoietic and Lymphoid Tissues4th edLyonIARC2008
   Google Scholar
• ListADewaldGBennettJLenalidomide in the myelodysplastic syndrome with chromosome 5q deletionN Engl J Med20063551456146517021321
   PubMed Web of Science ®Google Scholar
• FenauxPGiagounidisASelleslagDA randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5qBlood20111183765377621753188
   PubMed Web of Science ®Google Scholar
• ListAKurtinSRoeDJEfficacy of lenalidomide in myelodysplastic syndromesN Engl J Med200535254955715703420
   PubMed Web of Science ®Google Scholar
• RazaAReevesJAFeldmanEJPhase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5qBlood2008111869317893227
   PubMed Web of Science ®Google Scholar
• SekeresMAMaciejewskiJPGiagounidisAARelationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromesJ Clin Oncol2008265943594919018091
   PubMed Web of Science ®Google Scholar
• FehnigerTAByrdJCMarcucciGSingle-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13Blood20091131002100518824593
   PubMed Web of Science ®Google Scholar
• FehnigerTAUyGLTrinkausKA phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemiaBlood20111171828183321051557
   PubMed Web of Science ®Google Scholar
• SekeresMAGundackerHLancetJA phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605Blood201111852352821551228
   PubMed Web of Science ®Google Scholar
• ChenYKantarjianHEstrovZA phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalitiesClin Lymphoma Myeloma Leuk20121234134422579233
   PubMed Web of Science ®Google Scholar
• PlatzbeckerUGermingUCombination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?Leukemia2013271813181923644421
   PubMed Web of Science ®Google Scholar
• PlatzbeckerUBraulkeFKündgenASequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I studyLeukemia2013271403140723354011
   PubMed Web of Science ®Google Scholar
• Garcia-ManeroGDaverNGBorthakurGPhase I Study of the Combination of 5-Azacitidine Sequentially with High-Dose Lenalidomide in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)Blood20111181122
   Web of Science ®Google Scholar
• PollyeaDAKohrtHEGallegosLSafety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemiaLeukemia20122689390122033493
   PubMed Web of Science ®Google Scholar
• PollyeaDAZehnderJCoutreSSequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemiaHaematologica20139859159623242596
   PubMed Web of Science ®Google Scholar
• SchermanEMalakSPerotCGorinNCRubioMTIsnardFInterest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotypeLeukemia20122682282421997572
   PubMed Web of Science ®Google Scholar
• RamsinghGWesterveltPCashenAFA phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AMLLeukemia20132772572822828444
   PubMed Web of Science ®Google Scholar
• SekeresMATiuRVKomrokjiRPhase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromesBlood20121204945495122915641
   PubMed Web of Science ®Google Scholar
• TodaroJBollmannPWRotherETGiglioADAzacitidine and lenalidomide as an alternative treatment for refractory acute myeloid leukemia: a case reportSao Paulo Med J2014
   Web of Science ®Google Scholar
• AttarECAmreinPCFraserJWPhase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)Leuk Res2013371016102023773898
   PubMed Web of Science ®Google Scholar
• DennisMCulliganDKaramitrosDLenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalitiesLeuk Res Rep20132707424371786
   PubMedGoogle Scholar
• HabermannTMLossosISJusticeGLenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphomaBr J Haematol200914534434919245430
   PubMed Web of Science ®Google Scholar
• ZinzaniPLVoseJMCzuczmanMSLong-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 studyAnn Oncol2013242892289724030098
   PubMed Web of Science ®Google Scholar
• EveHECareySRichardsonSJSingle-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differencesBr J Haematol201215915416322881386
   PubMed Web of Science ®Google Scholar
• GoyASinhaRWilliamsMESingle-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) studyJ Clin Oncol2013313688369524002500
   PubMed Web of Science ®Google Scholar
• WuLAdamsMCarterTlenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cellsClin Cancer Res2008144650465718628480
   PubMed Web of Science ®Google Scholar
• WangMFayadLWagner-BartakNLenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trialLancet Oncol20121371672322677155
   PubMed Web of Science ®Google Scholar
• ZajaFDe LucaSVitoloUSalvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkersHaematologica20129741642222058200
   PubMed Web of Science ®Google Scholar
• FlinnIWMainwaringMPeacockNRituximab, Lenalidomide, and Bortezomib in the First-Line or Second-Line Treatment of Patients with Mantle Cell Lymphoma a Phase I/II TrialASH Annual Meeting Abstracts20121202748
   Google Scholar
• MorrisonVAJungS-HJohnsonJSalvage Therapy with Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Initial Results of a Phase II Trial (Alliance/CALGB 50501)ASH Annual Meeting Abstracts20121203696
   Google Scholar
• TrnenyMLamyTWalewskiJPhase II Randomized, Multicenter Study of Lenalidomide Vs Best Investigator’s Choice in Relapsed/Refractory Mantle Cell Lymphoma: Results of the MCL-002 (SPRINT) StudyASH Annual Meeting Abstracts2014124626
   Google Scholar
• RuanJMartinPShahBDSustained Remission with the Combination Biologic Doublet of Lenalidomide Plus Rituximab As Initial Treatment for Mantle Cell Lymphoma: A Multi-Center Phase II Study ReportASH Annual Meeting Abstracts2014124
   Google Scholar
• WiernikPHLossosISTuscanoJMLenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphomaJ Clin Oncol2008264952495718606983
   PubMed Web of Science ®Google Scholar
• WitzigTEVoseJMZinzaniPLAn international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphomaAnn Oncol2011221622162721228334
   PubMed Web of Science ®Google Scholar
• AlizadehAAEisenMBDavisREDistinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature200040350351110676951
   PubMed Web of Science ®Google Scholar
• RosenwaldAWrightGChanWCThe use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphomaN Engl J Med20023461937194712075054
   PubMed Web of Science ®Google Scholar
• Hernandez-IlizaliturriFJDeebGZinzaniPLHigher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotypeCancer20111175058506621495023
   PubMed Web of Science ®Google Scholar
• ZinzaniPLPellegriniCGandolfiLCombination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trialClin Lymphoma Myeloma Leuk20111146246621859554
   PubMed Web of Science ®Google Scholar
• WangMFowlerNWagner-BartakNOral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trialLeukemia2013271902190923545991
   PubMed Web of Science ®Google Scholar
• FeldmanTMatoARChowKFAddition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphomaBr J Haematol2014166778324661044
   PubMed Web of Science ®Google Scholar
• CzuczmanMSDaviesALintonKMA Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator’s Choice in Relapsed/Refractory DLBCLASH Annual Meeting Abstracts2014124
   Google Scholar
• ChiappellaATucciACastellinoALenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana LinfomiHaematologica2013981732173823812930
   PubMed Web of Science ®Google Scholar
• VitoloUChiappellaAFranceschettiSLenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trialLancet Oncol20141573073724831981
   PubMed Web of Science ®Google Scholar
• NowakowskiGSLaPlantBMaconWRLenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-Cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II studyJ Clin Oncol201533325125725135992
   PubMed Web of Science ®Google Scholar
• ReddyNMMorganDSParkSIGreerJPRichardsKLPhase II Randomized Study Of Lenalidomide Or Lenalidomide and Rituximab As Maintenance Therapy Following Standard Chemotherapy For Patients With Intermediate-High/High Risk Diffuse Large B-Cell Lymphoma (DLBCL)Blood201312221
   Web of Science ®Google Scholar
• TuscanoJMDutiaMCheeKLenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphomaBr J Haematol201416537538124606326
   PubMed Web of Science ®Google Scholar
• LeonardJJungS-HJohnsonJLCALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphomaASCO Meeting Abstracts2012308000
   Google Scholar
• FowlerNHDavisRERawalSSafety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trialLancet Oncol2014151311131825439689
   PubMed Web of Science ®Google Scholar
• KimbyEMartinelliGOstenstadBRituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10ASH Annual Meeting Abstracts2014124
   Google Scholar
• Chanan-KhanAMillerKCMusialLClinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II studyJ Clin Oncol2006245343534917088571
   PubMed Web of Science ®Google Scholar
• FerrajoliALeeBNSchletteEJLenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemiaBlood20081115291529718334676
   PubMed Web of Science ®Google Scholar
• BadouxXCKeatingMJWenSPhase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemiaJ Clin Oncol20133158459123270003
   PubMed Web of Science ®Google Scholar
• BadouxXCKeatingMJWenSLenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemiaBlood20111183489349821725050
   PubMed Web of Science ®Google Scholar
• ChenCIBergsagelPLPaulHSingle-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemiaJ Clin Oncol2011291175118121189385
   PubMed Web of Science ®Google Scholar
• JamesDFWernerLBrownJRLenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortiumJ Clin Oncol2014322067207324868031
   PubMed Web of Science ®Google Scholar
• ZinzaniPLPellegriniCBroccoliALenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specifiedLeuk Lymphoma2011521585158821504290
   PubMed Web of Science ®Google Scholar
• MorschhauserFFitoussiOHaiounCA phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trialEur J Cancer2013492869287623731832
   PubMed Web of Science ®Google Scholar
• HopfingerGNösslingerTLangALenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trialAnn Hematol20149345946224441915
   PubMed Web of Science ®Google Scholar
• FehnigerTALarsonSTrinkausKA phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphomaBlood20111185119512521937701
   PubMed Web of Science ®Google Scholar
• RevickiDABrandenburgNAMuusPYuRKnightRFenauxPHealth-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trialLeuk Res20133725926523273538
   PubMed Web of Science ®Google Scholar
• DimopoulosMADelforgeMHájekRLenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trialHaematologica20139878478823242595
   PubMed Web of Science ®Google Scholar
• DelforgeMMinukLEisenmannJ-CHealth-related quality of life (HRQOL) in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Results from the first trialASCO Meeting Abstracts2014328516
   Google Scholar